HeartBeam, Inc. a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics technology, bringing together two innovation leaders in ambulatory electrocardiogram (ECG) recording and analysis. The initial collaboration aims to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, available on HeartBeam’s devices.*

This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring,” said Robert Eno, Chief Executive Officer of HeartBeam. “AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.”

HeartBeam’s groundbreaking credit card-sized, cable-free 3D ECG device captures the heart’s electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG using a personalized transformation matrix. HeartBeam plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software.

Adding AccurKardia’s FDA-cleared, device-agnostic automated ECG interpretation platform to HeartBeam’s device will enhance HeartBeam’s subsequent commercial offering for arrhythmia assessment by enabling patients and physicians to get an automated rhythm assessment which will facilitate a quicker diagnosis and faster access to clinical care when needed. The strategic collaboration is expected to expedite HeartBeam’s product development efforts, reducing both costs and timelines.

 

Source: businesswire.com

Report Abuse